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stimulator (BLyS) monoclonal antibody, 
is the first biologic drug licensed for SLE 
treatment.
Case report
We report the case of a 24 years old wo-
man, who attended our outpatient clinic in 
February 2012 because of intense joint pain 
IntroduCtIon
Systemic Lupus Erythematosus (SLE) is 
a systemic autoimmune disease, whose se-
verity and clinical manifestations are highly 
variable. SLE pathogenesis is not completely 
known; however, genetic factors, as well as 
hormonal and environmental triggers, play a 
role in the development of the abnormal im-
mune response [1]. SLE diagnosis is based 
on clinical features and laboratory findings 
according to current classification criteria 
[2,3]. SLE is a chronic disease and its course 
is characterized by relapses and remission 
periods. Therefore, the clinician should set 
up SLE treatment according to clinical ma-
nifestations and severity of flares [4].
Current therapy includes nonsteroidal 
anti-inflammatory drugs, corticosteroids, 
anti-malarial agents and immunosuppressi-
ve drugs. Belimumab, an anti-B lymphocyte 
Why we do describe this case:
 y A severe form of SLE with several di-
sease flares
 y Non-response to standard therapy
 y Fast and long-term remission obtained 
with anti-BLyS monoclonal antibody 
belimumab
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Case report
abstract
Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by complex 
pathophysiology and heterogeneous clinical picture. Belimumab is the first biological therapy 
licensed for SLE.
We report the case of a 24 years old woman affected by a severe form of systemic lupus erythematosus 
with arthritis, muscle weakness, cervical lymphadenopathy, cutaneous involvement, fever, 
leukopenia, low complement levels and positivity for anti-dsDNA antibodies. Treatment with 
high dose steroids, hydroxychloroquine, and mycophenolate mofetil did not induce remission and 
several disease flares were observed. Therapy with anti-BLyS monoclonal antibody belimumab 
leads to a fast clinical and laboratory response and to stable remission lasting for 30 months 
allowing steroid tapering to very low maintenance dose.
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Efficacia di belimumab nel trattamento di un caso di lupus eritematoso sistemico grave non 
rispondente alla terapia standard
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stopped, and the patient received methyl-
prednisolone (five 500 mg i.v. infusions) 
followed by prednisone 1 mg/kg/day with 
transient but unsatisfactory clinical impro-
vement (Figure 1).
On the basis of the poor disease control 
obtained with the previous treatments, we 
decided to start therapy with the anti-BLyS 
monoclonal antibody belimumab (10 mg/
kg) according to the good results obtained 
by this biological drug in SLE patients re-
fractory to standard therapy [4-8]. At the 
time of the first belimumab administration 
( June 2013) the patient was on treatment 
only with prednisone 25 mg/daily. No other 
lupus-specific medications were continued 
while she was on belimumab. The first three 
infusions were given 14 days apart and were 
followed by monthly infusions. We observed 
a disappearance of arthralgia and constitu-
tional symptoms such as fatigue and fever, 
30 days after belimumab was initiated. He-
matological parameters and C3 and CRP 
values reached the normal level after three 
months of therapy. The amelioration of cli-
nical and laboratory data allowed to decre-
ase the prednisone daily dose from 25 mg to 
18.5 mg after 4 months from the beginning 
of belimumab treatment.
Nowadays, the patient has received 33 
belimumab monthly infusions which were 
well tolerated without any side effect. This 
therapy leads to a stable remission lasting 
for 30 months in the absence of disease fla-
res and allowed a further tapering of the 
prednisone daily dosage to 2 mg (Figure 2).
Figure 1. Trend of 
laboratory parameters 
before and during 
belimumab treatment. 
The vertical line 
represents the start of 
belimumab
ESR = Erythrocyte 
Sedimentation Rate
CRP = C-reactive protein
Figure 2. Trend 
of SLEDAI score 
(Systemic Lupus 
Erythematosus Disease 
Activity Index) and 
prednisone dose before 
and during belimumab 
treatment. The vertical 
line represents the start 
of belimumab
Main questions the clinician should ask himself facing such a 
patient:
 y Which are the clinical symptoms and laboratory data suggesting the 
lack of response to standard therapy?
 y How many disease flares should arise to decide to switch from stan-
dard therapy to biological drugs?
 y Which are the potential side effects of the long-term biological tre-
atment?
localized at knees, hands and wrists. She re-
ported a history of asthma and allergic rhi-
nitis (dust mites, dog dander, and olive tree 
pollen) for which she underwent sublingual 
immunotherapy in 2010. This therapy was 
withdrawn because a lack of benefit after 
two years.
Clinically, she complained of arthritis, 
muscle weakness, cervical lymphadenopathy 
and fever associated with leukopenia (white 
blood cells: 2,640 x 109/µl), low complement 
levels (C3: 75 mg/dl, C4: 19 mg/dl) and 
increased erythrocyte sedimentation rate 
(ESR: 55 mm/h) and C-reactive protein 
(CRP: 14 mg/l) levels. Urinalysis was un-
remarkable. Immunological investigations 
showed positivity of antinuclear (ANA, 
1:1280 titer with homogenous pattern), anti-
double stranded DNA (ds-DNA) and SSA-
Ro antibodies; antineutrophil cytoplasm 
antibodies (ANCA) and antiphospholipid 
antibodies were negative. Clinical features 
and laboratory data lead to the diagnosis of 
systemic lupus erythematosus (SLE) accor-
ding to current criteria [2,3].
The patient was first treated with predni-
sone (1 mg/kg/day), gradually tapered to 
12.5 mg/day, associated with hydroxychlo-
roquine (HCQ) (200 mg twice a day), which 
did not provide clinical benefit. Then, after 
a cutaneous flare, in November 2012 HCQ 
was stopped and mycophenolate mofetil 
(MMF) (2 g/daily) was started in associa-
tion with glucocorticoids at variable doses 
according to clinical needs. Despite these 
medications, the disease was unsatisfactory 
controlled.
In May 2013, she presented fever (39° C), 
fatigue, intense knees’ pain and swelling, and 
was admitted to our Department of Internal 
Medicine, Clinical Immunology Unit. 
Physical examination revealed severe knees’ 
inflammation, tachycardia, and a soft systo-
lic cardiac murmur. Chest X-ray was nega-
tive. She also presented cutaneous signs as 
livedo reticularis and dermographism. Labo-
ratory data showed worsening of leukopenia 
(1.7 x 109/µl) with severe lymphopenia (0.3 
x109/µl) associated with mild anemia and 
thrombocytopenia (62 x 109/µl), abnormal 
liver function tests (AST 145 U/l; ALT 155 
U/l) and increased LDH level (1680 U/l). 
The severe inflammatory status was confir-
med by high CRP (17.1 mg/l) and ferritin 
(29,799 µg/l) levels. Blood and urine cultu-
res were negative. A transthoracic Doppler 
echocardiography showed normal valvular 
structures without signs of endocarditis as 
well as normal systolic and diastolic fun-
ctions. Serology resulted negative for Cyto-
megalovirus infection but was positive for a 
recent Epstein-Barr virus infection (positi-
vity of VCA IgM and EBNA 1 IgG anti-
bodies). A computer tomography scan sho-
wed liver and spleen enlargement, compati-
ble with the viral infection, and no signs of 
malignancy. In accordance with these clini-
cal features and laboratory results, we hypo-
thesized an SLE flare triggered by EBV 
infection. During hospitalization, MMF was 
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stopped, and the patient received methyl-
prednisolone (five 500 mg i.v. infusions) 
followed by prednisone 1 mg/kg/day with 
transient but unsatisfactory clinical impro-
vement (Figure 1).
On the basis of the poor disease control 
obtained with the previous treatments, we 
decided to start therapy with the anti-BLyS 
monoclonal antibody belimumab (10 mg/
kg) according to the good results obtained 
by this biological drug in SLE patients re-
fractory to standard therapy [4-8]. At the 
time of the first belimumab administration 
( June 2013) the patient was on treatment 
only with prednisone 25 mg/daily. No other 
lupus-specific medications were continued 
while she was on belimumab. The first three 
infusions were given 14 days apart and were 
followed by monthly infusions. We observed 
a disappearance of arthralgia and constitu-
tional symptoms such as fatigue and fever, 
30 days after belimumab was initiated. He-
matological parameters and C3 and CRP 
values reached the normal level after three 
months of therapy. The amelioration of cli-
nical and laboratory data allowed to decre-
ase the prednisone daily dose from 25 mg to 
18.5 mg after 4 months from the beginning 
of belimumab treatment.
Nowadays, the patient has received 33 
belimumab monthly infusions which were 
well tolerated without any side effect. This 
therapy leads to a stable remission lasting 
for 30 months in the absence of disease fla-
res and allowed a further tapering of the 
prednisone daily dosage to 2 mg (Figure 2).
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Main questions the clinician should ask himself facing such a 
patient:
 y Which are the clinical symptoms and laboratory data suggesting the 
lack of response to standard therapy?
 y How many disease flares should arise to decide to switch from stan-
dard therapy to biological drugs?
 y Which are the potential side effects of the long-term biological tre-
atment?
dIsCussIon
Despite the current incomplete under-
standing of SLE pathogenesis, it is well 
known that B cells play a key role in the 
development of the disease mainly through 
the production of autoantibodies. Belimu-
mab represents the first biological targeted 
therapy licensed for the treatment of SLE 
patients with active disease not responding 
to conventional therapies [5]. Belimumab is 
a fully human IgG1λ recombinant mono-
clonal antibody directed against soluble B 
lymphocyte stimulator (BLyS, also known 
as BAFF), a member of the tumor necrosis 
factor (TNF) family. BLyS is involved in 
lymphocyte survival, activation, and proli-
feration. In the context of an autoimmune 
disorder such as SLE, elevated BLyS levels 
contribute to autoantibodies production and 
immune-complexes formation leading to in-
flammatory response and tissue damage. The 
interaction between belimumab and soluble 
BLyS prevents the binding of this growth 
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hypertension, diabetes, weight gain and oste-
oporosis are well-known. These side effects 
could be reduced using a low maintenance 
daily dose < 7.5 mg [9]. Accordingly, the 
clinician should consider the best treatment 
strategy to reduce steroid dose to the lowest 
possible amount. In our case, belimumab 
allowed a quick tapering of prednisone wi-
thout recurrence of the disease. Neverthe-
less, as belimumab is a relative young drug, 
more experience is required to ameliorate 
its management and to know its long-term 
efficacy and potential side effects.
factor with its receptors thus decreasing B-
cell survival and autoantibodies production.
Since 2013, we have treated with belimu-
mab 10 SLE patients who were refractory to 
standard therapy. Among them, 7 showed a 
fast and long-standing response whereas 3 
discontinued belimumab for inefficacy. Here 
we report the successful treatment with be-
limumab of a young woman with uncon-
trolled severe active SLE not responding to 
conventional treatment. Among the wide 
spectrum of drugs used for SLE therapy, 
corticosteroids are commonly used. Side 
effects of long-term corticosteroid intake as 
